Abstract:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to induce apoptosis in prostate cancer cells through DR4 and DR5 death receptors, but not in normal prostate cells, which do not express these receptors. Therefore, TRAIL has excellent potential to be a selective prostate cancer therapeutic agent with minimal toxic side effects. However, prostate cancer cells, as many other cancer types, develop resistance to TRAIL, and the underlying molecular mechanisms require further investigation. We hypothesize that selenium may sensitize TRAIL-resistant cells to undergo caspase-mediated apoptosis and increase therapeutic efficacy. Here, we report that TRAIL signaling in LNCaP prostate cancer cells stalled at downstream of caspase-8 and BID cleavage, as indicated by the lack of Bax translocation into mitochondria, and no subsequent activation of the caspase-9 cascade. Selenite induced a rapid generation of superoxide and p53 Ser(15) phosphorylation and increased Bax abundance and translocation into the mitochondria. Selenite and TRAIL combined treatment led to synergistic increases of Bax abundance and translocation into mitochondria, loss of mitochondrial membrane potential, cytochrome c release, and cleavage activation of caspase-9 and caspase-3. Inactivating p53 with a dominant-negative mutant abolished apoptosis without affecting superoxide generation, whereas a superoxide dismutase mimetic agent blocked p53 activation, Bax translocation to mitochondria, cytochrome c release, and apoptosis induced by selenite/TRAIL. In support of Bax as a crucial target for cross-talk between selenite and TRAIL pathways, introduction of Bax into p53 mutant DU145 cells enabled selenite to sensitize these cells for TRAIL-induced apoptosis. Taken together, the results indicate that selenite induces a rapid superoxide burst and p53 activation, leading to Bax up-regulation and translocation into mitochondria, which restores the cross-talk with stalled TRAIL signaling for a synergistic caspase-9/3 cascade-mediated apoptosis execution.

Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression.

2-Tellurium-bridged Β-Cyclodextrin, a Thioredoxin Reductase Inhibitor, Sensitizes Human Breast Cancer Cells to TRAIL-induced Apoptosis Through DR5 Induction and NF-κB Suppression.

Selenocysteine Derivative Overcomes TRAIL Resistance in Melanoma Cells: Evidence for ROS-dependent Synergism and Signaling Crosstalk.

TRAIL-driven Targeting and Reversing Cervical Cancer Radioresistance by Seleno-Nanotherapeutics Through Regulating Cell Metabolism

Novel Insights into the Synergistic Interaction of a Thioredoxin Reductase Inhibitor and TRAIL: the Activation of the ASK1-ERK-Sp1 Pathway

Trichosanthin Enhances Sensitivity Of Non-Small Cell Lung Cancer (Nsclc)Trail-Resistance Cells

Hsp90 Inhibitor SNX-2112 Enhances TRAIL-Induced Apoptosis of Human Cervical Cancer Cells Via the ROS-Mediated JNK-p53-Autophagy-DR5 Pathway

Selenadiazole Derivatives As Theranostic Agents for Simultaneous Cancer Chemo-/Radiotherapy by Targeting Thioredoxin Reductase

Sensitization of Cancer Cells to Radiation by Selenadiazole Derivatives by Regulation of ROS-mediated DNA Damage and ERK and AKT Pathways.

CCT327 enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistant human leukemia cells.

Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway

Synergism Between Thioredoxin Reductase Inhibitor Ethaselen and Sodium Selenite in Inhibiting Proliferation and Inducing Death of Human Non-Small Cell Lung Cancer Cells.

Selenadiazole Derivative-Loaded Metal Azolate Frameworks Facilitate NK Cell Immunotherapy by Sensitizing Tumor Cells and Shaping Immuno-Suppressive Microenvironments.

Dual-functional Se/Fe Complex Facilitates TRAIL Treatment Against Resistant Tumor Cells Via Modulating Cellular Endoplasmic Reticulum Stress

20(S)-Ginsenoside Rh2 Promotes TRAIL-induced Apoptosis by Upregulating DR5 in Human Hepatocellular Carcinoma Cells

Selenocystine Potentiates Cancer Cell Apoptosis Induced by 5-Fluorouracil by Triggering Reactive Oxygen Species-Mediated DNA Damage and Inactivation of the ERK Pathway

Reversal of the Apoptotic Resistance of Non-Small-Cell Lung Carcinoma Towards TRAIL by Natural Product Toosendanin

Inorganic Selenium Sensitizes Prostate Cancer Cells to TRAIL-induced Apoptosis Through Superoxide/p53/bax-Mediated Activation of Mitochondrial Pathway

Rational Design of Cancer-Targeted Selenadiazole Derivative As Efficient Radiosensitizer for Precise Cancer Therapy

N-Acetyl-Glucosamine Sensitizes Non-Small Cell Lung Cancer Cells to TRAIL-Induced Apoptosis by Activating Death Receptor 5